Headache News and Research

Latest Headache News and Research

John Snow Labs launches new Data Market to help healthcare and life science innovators

John Snow Labs, an award-winning global data operations and AI company, today announces the launch of John Snow Labs Data Market. The Data Market is an online store that allows users to subscribe to datasets and/or data packages in the healthcare and life science domain.

13 Nov 2018

Anopheles species may be important vectors driving spread of Mayaro virus in the U.S.

Mosquitoes of the genus Anopheles are well known as primary vectors of malaria. But a new study suggests that Anopheles species, including some found in the United States, also are capable of carrying and transmitting an emerging pathogen, Mayaro virus, which has caused outbreaks of disease in South America and the Caribbean.

9 Nov 2018

House Dems in new seats of power will steer health policy, attack drug prices

For the first time since passing the Affordable Care Act, Democrats will soon control the House of Representatives and its powerful health committees. But Republicans' tightened grip on the Senate means those hoping for another round of dramatic, progressive reforms may be disappointed.

7 Nov 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

TherapeuticsMD announces FDA approval of BIJUVA capsules to manage vasomotor symptoms of menopause

TherapeuticsMD, Inc., an innovative women's healthcare company, today announced that the United States Food and Drug Administration has approved BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.

29 Oct 2018

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Biogen and Eisai Co., Ltd. announced that Biogen presented results at the Clinical Trials on Alzheimer's Disease meeting, in Barcelona, Spain, from the recent 36- and 48-month analyses of the ongoing long-term extension of the Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment due to Alzheimer's disease and mild AD.

29 Oct 2018

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.

26 Oct 2018

Stroke 'mimics' and 'chameleons' can complicate accurate diagnoses

Stroke specialists often see conditions known as stroke "mimics" and "chameleons" that can complicate accurate diagnoses, Loyola Medicine neurologists report in the November 2018 issue of Neuroimaging Clinics of North America.

26 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.

22 Oct 2018

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.

22 Oct 2018

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.

22 Oct 2018

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients.

22 Oct 2018

Medicare for all? CMS chief warns program has enough problems already

The Trump administration's top Medicare official Tuesday slammed the federal health program as riddled with problems that hinder care to beneficiaries, increase costs for taxpayers and escalate fraud and abuse.

16 Oct 2018

Eisai enters into agreement with Eurofarma for development and sales of lorcaserin in 17 countries

Eisai Co., Ltd. has entered into an agreement to grant exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride (generic name, product name in the United States: BELVIQ, product name for once-daily formulation in the United States: BELVIQ XR, "lorcaserin") in 17 countries in Latin America and the Caribbean, excluding Brazil, to Eurofarma Laboratorios S.A. which has a business foundation in Latin America.

16 Oct 2018

Researchers identify strategies to help teens with type 1 diabetes protect their hearts

People with type 1 diabetes are far more likely to develop cardiovascular disease than those without diabetes. Their risks climb even higher if they show signs of hypertension (high blood pressure) or dyslipidemia (unhealthy levels of cholesterol or triglycerides).

12 Oct 2018

Common gene variants linked to migraine risk in African-American children

Pediatric researchers have discovered common gene variants associated with migraines in African-American children.

11 Oct 2018

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network added COPIKTRA (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for follicular lymphoma.

8 Oct 2018

Pilot study shows how migraine can be treated without medicine

By slightly changing the body's own molecules using a small inhaler, certain migraine patients can either cut down on medication or do without it completely. This is shown by a pilot study which has been published in the scientific journal Cephalalgia.

4 Oct 2018

Headache News and Research

Latest Headache News and Research

John Snow Labs launches new Data Market to help healthcare and life science innovators

Anopheles species may be important vectors driving spread of Mayaro virus in the U.S.

House Dems in new seats of power will steer health policy, attack drug prices

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

TherapeuticsMD announces FDA approval of BIJUVA capsules to manage vasomotor symptoms of menopause

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Stroke 'mimics' and 'chameleons' can complicate accurate diagnoses

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Medicare for all? CMS chief warns program has enough problems already

Eisai enters into agreement with Eurofarma for development and sales of lorcaserin in 17 countries

Researchers identify strategies to help teens with type 1 diabetes protect their hearts

Common gene variants linked to migraine risk in African-American children

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Pilot study shows how migraine can be treated without medicine

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Headache News and Research

Latest Headache News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in